#fda fast-track

A Paradigm Shift? Trump Administration Fast-Tracks Psychedelic Drug Review for Mental Health

In a groundbreaking move that could redefine mental health treatment, the Trump administration on April 18, 2026, signed an executive order to dramatically accelerate the review process for psychedelic drugs. This directive aims to expedite research and access to substances like psilocybin and ibogaine, offering a glimmer of hope to millions grappling with severe mental health disorders.